Since 2019, the INADcure Foundation has collaborated with Dr. Hugo Bellen and Dr. Guang Lin at the Bellen Lab, located within Baylor College of Medicine. This partnership has been pivotal in advancing our understanding of INAD. Through grant-funded research, considerable strides have been made in unraveling the molecular function and underlying mechanisms of this disease. Their investigations have explored potential therapeutic strategies, including modulating retromer, sphingolipid, and endolysosomal pathways in fibroblasts of INAD patients and developing AAV-based gene therapy approaches for INAD in mice models. These efforts resulted in a 2023 publication titled “Exploring therapeutic strategies for infantile neuronal axonal dystrophy (INAD/PARK14),” making their findings and insights accessible to the wider scientific community and underscoring the importance of this collaborative work in the ongoing effort to find a cure for INAD.